Cord Blood HSC Unit
Hematologic Malignancies
Key Facts
About Global Cord Blood
Global Cord Blood Corporation is a dominant player in the Chinese cord blood banking industry, operating through its subsidiaries in key regions like Beijing, Guangdong, and Zhejiang. The company's core business is the preservation of hematopoietic stem cells from umbilical cord blood, which are used in transplant medicine for treating various blood and immune system disorders. It has established a significant market presence and a large stored inventory, positioning it as a critical infrastructure provider in the regenerative medicine sector in China. The company faces a dynamic regulatory environment and competition but benefits from first-mover advantages and established operational scale.
View full company profileAbout Global Cord Blood
Global Cord Blood Corporation is a dominant player in the Chinese cord blood banking industry, operating through its subsidiaries in key regions like Beijing, Guangdong, and Zhejiang. The company's core business is the preservation of hematopoietic stem cells from umbilical cord blood, which are used in transplant medicine for treating various blood and immune system disorders. It has established a significant market presence and a large stored inventory, positioning it as a critical infrastructure provider in the regenerative medicine sector in China. The company faces a dynamic regulatory environment and competition but benefits from first-mover advantages and established operational scale.
View full company profileAbout Global Cord Blood
Global Cord Blood Corporation is a dominant player in the Chinese cord blood banking industry, operating through its subsidiaries in key regions like Beijing, Guangdong, and Zhejiang. The company's core business is the preservation of hematopoietic stem cells from umbilical cord blood, which are used in transplant medicine for treating various blood and immune system disorders. It has established a significant market presence and a large stored inventory, positioning it as a critical infrastructure provider in the regenerative medicine sector in China. The company faces a dynamic regulatory environment and competition but benefits from first-mover advantages and established operational scale.
View full company profileAbout Global Cord Blood
Global Cord Blood Corporation is a dominant player in the Chinese cord blood banking industry, operating through its subsidiaries in key regions like Beijing, Guangdong, and Zhejiang. The company's core business is the preservation of hematopoietic stem cells from umbilical cord blood, which are used in transplant medicine for treating various blood and immune system disorders. It has established a significant market presence and a large stored inventory, positioning it as a critical infrastructure provider in the regenerative medicine sector in China. The company faces a dynamic regulatory environment and competition but benefits from first-mover advantages and established operational scale.
View full company profileAbout Global Cord Blood
Global Cord Blood Corporation is a dominant player in the Chinese cord blood banking industry, operating through its subsidiaries in key regions like Beijing, Guangdong, and Zhejiang. The company's core business is the preservation of hematopoietic stem cells from umbilical cord blood, which are used in transplant medicine for treating various blood and immune system disorders. It has established a significant market presence and a large stored inventory, positioning it as a critical infrastructure provider in the regenerative medicine sector in China. The company faces a dynamic regulatory environment and competition but benefits from first-mover advantages and established operational scale.
View full company profileTherapeutic Areas
Other Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1905 | Jiangsu Hengrui Medicine | Phase 1 |
| Rituximab biosimilar (IBI301) | Innovent Biologics | Approved |
| Alemtuzumab Biosimilar | CSPC Pharmaceutical Group Limited | Phase 3 |
| Lead CAR-T Program | Arcellx | Phase 1 |
| KT-333 | Kymera Therapeutics | Phase 1 |
| Undisclosed CAR-T programs | Beam Therapeutics | Discovery/Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| Trichostatin A (TSA) | Vanda Pharmaceuticals | Oncology Program |
| TSC-102-A01 | TScan Therapeutics | Preclinical |
| TSC-102-A03 | TScan Therapeutics | Preclinical |
| LBL-007 | LakeShore Biopharma | Phase 1 |
| CER-T Cell Platform | CERo Therapeutics | Pre-clinical |